320 related articles for article (PubMed ID: 38473804)
1. Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches.
Pastena P; Perera H; Martinino A; Kartsonis W; Giovinazzo F
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473804
[TBL] [Abstract][Full Text] [Related]
2. Biology and Management of Patients With Triple-Negative Breast Cancer.
Sharma P
Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
[TBL] [Abstract][Full Text] [Related]
3. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
4. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
5. The evolving management of metastatic triple negative breast cancer.
Malhotra MK; Emens LA
Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
[TBL] [Abstract][Full Text] [Related]
6. Genetic Markers in Triple-Negative Breast Cancer.
Sporikova Z; Koudelakova V; Trojanec R; Hajduch M
Clin Breast Cancer; 2018 Oct; 18(5):e841-e850. PubMed ID: 30146351
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
8. Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.
Diana A; Franzese E; Centonze S; Carlino F; Della Corte CM; Ventriglia J; Petrillo A; De Vita F; Alfano R; Ciardiello F; Orditura M
Curr Oncol Rep; 2018 Aug; 20(10):76. PubMed ID: 30128845
[TBL] [Abstract][Full Text] [Related]
9. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
Qattan A
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255471
[TBL] [Abstract][Full Text] [Related]
10. Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker.
O'Conor CJ; Chen T; González I; Cao D; Peng Y
Biomark Med; 2018 Jul; 12(7):813-820. PubMed ID: 29902924
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
12. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
Sharma P
Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.
Dees S; Pontiggia L; Jasmin JF; Mercier I
Cancer Biol Ther; 2020 Jun; 21(6):506-521. PubMed ID: 32164483
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and immunohistochemical characteristics of breast cancer patients from Northeast India with special reference to triple negative breast cancer: A prospective study.
Sultana R; Kataki AC; Barthakur BB; Sarma A; Bose S
Curr Probl Cancer; 2020 Oct; 44(5):100556. PubMed ID: 32044043
[TBL] [Abstract][Full Text] [Related]
15. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Le Du F; Eckhardt BL; Lim B; Litton JK; Moulder S; Meric-Bernstam F; Gonzalez-Angulo AM; Ueno NT
Oncotarget; 2015 May; 6(15):12890-908. PubMed ID: 25973541
[TBL] [Abstract][Full Text] [Related]
16. The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials.
Huynh MM; Pambid MR; Jayanthan A; Dorr A; Los G; Dunn SE
Expert Opin Investig Drugs; 2020 Nov; 29(11):1199-1208. PubMed ID: 32869671
[TBL] [Abstract][Full Text] [Related]
17. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
Cao W; Li J; Hao Q; Vadgama JV; Wu Y
Breast Cancer Res; 2019 Feb; 21(1):29. PubMed ID: 30791936
[TBL] [Abstract][Full Text] [Related]
18. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
Mehlich D; Marusiak AA
Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
[TBL] [Abstract][Full Text] [Related]
19. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
Anders CK; Abramson V; Tan T; Dent R
Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
[TBL] [Abstract][Full Text] [Related]
20. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]